Inventiva: NATiV3 study pause lifted

(CercleFinance.com) - Inventiva announces that it has lifted the previously announced voluntary pause in screening and randomization for its NATiV3 clinical trial evaluating lanifibranor in NASH (non-alcoholic fatty liver disease), and has resumed screening activities at its sites.


The biopharmaceutical company recalls that it decided to suspend the trial following a suspected serious unexpected adverse event (SUSAR) in a study patient, in order to implement the recommendations of the independent Data Monitoring Committee.

Screening of patients is resuming at sites operating under the aegis of the central IRB in the USA, and others are expected to resume progressively over the coming weeks. The first visit by the last patient is scheduled for the first half of 2024.

Copyright (c) 2024 CercleFinance.com. All rights reserved.